Indefinite Delivery Contract 75N93023D00002
Award Date
4/15/23
Last Date to Order
4/14/30
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Sri International
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Sri International to provide preclinical development support for candidate products and drug development activities. The $107.3M contract has a 7-year period of performance from October 2020 to October 2027.
The contract encompasses a broad scope of work, including in vitro testing and screening,...
The National Institute of Allergy and Infectious Diseases has awarded an Indefinite Delivery/Indefinite Quantity contract to Sri International to support medical countermeasure development efforts. Task orders issued to date involve animal model development, efficacy testing, and clinical safety studies for monoclonal antibodies, vaccines, and therapeutics against infectious disease targets. Work is conducted at Sri International's facility in West Menlo Park, California over periods ranging...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an indefinite delivery/indefinite quantity contract valued at $98.9 million to Lovelace Biomedical Research Institute under the Resources to Advance Pediatrics and HIV Prevention Science master contract. The contract aims to procure preclinical development support services for HIV, pediatric, and prevention products through April 2030. Services include preclinical gap filling, animal model studies,...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to support preclinical and translational vaccine development services for HIV vaccines and other candidate agents. The total potential value of the contracts is $364,553,934 over a seven-year period of performance from December 2021 through November 2028.
The contracts will provide a broad range of capabilities required for preclinical and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract valued at up to $98,878,757 to multiple vendors under the Resources to Advance Pediatrics and HIV Prevention Science master contract. Tulane University received a $21,632 delivery order as the prime contractor to support the goals of the master contract in New Orleans, Louisiana from April 2023 through June 2024 on a cost-no-fee basis.
The originating...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, awarded a multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The $107.3 million contract has a 7-year period of performance from...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded this multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B, hepatitis C, and tuberculosis. The $107.3 million contract has a 7-year period of performance and encompasses seven task areas, including in vitro testing, synthesis of...
The National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The scope of work encompasses seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation...